| Type | Public |
| HQ | Rockville, US |
| Founded | 2009 |
| Size (employees) | 107 (est)+13% |
| Website | regenxbio.com |
Regenxbio was founded in 2009 and is headquartered in Rockville, US
Report incorrect company information
Viewing summary data as a guest
Sign up for free to see all dataKey People/Management at Regenxbio
Ken Mills
President and Chief Executive Officer
Vit Vasista
CFO
Stephen Yoo
Chief Medical Officer
Olivier Danos
Chief Scientific Officer
Curran Simpson
Senior Vice President, Technical Operations
Kimberly Sloan
Senior Vice President, Human Resources
Report incorrect company information
Regenxbio Office Locations
Regenxbio has an office in Rockville
Rockville, (HQ)
100 9712 Medical Center Dr
Report incorrect company information
Regenxbio Financials and Metrics
Regenxbio Revenue
Regenxbio's revenue was reported to be $10.39 m in FY, 2017
| USD | |
|---|---|
Revenue (Q3, 2018) | 5.3m |
Gross profit (Q3, 2018) | 4.8m |
Gross profit margin (Q3, 2018), % | 90.3% |
Net income (Q3, 2018) | (19.2m) |
EBIT (Q3, 2018) | (22.7m) |
Market capitalization (4-Dec-2018) | 2.0b |
Closing stock price (4-Dec-2018) | 54.6 |
Cash (30-Sep-2018) | 142.4m |
Regenxbio's current market capitalization is $2 b.
Annual
Annual
Quarterly
| USD | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
Cash | 205.3m | 35.5m | 30.1m | 28.1m | 82.0m | 57.6m | 59.9m | 71.9m | 106.9m | 142.4m |
Accounts Receivable | 2.0m | 783.0k | 679.0k | 228.0k | 50.0k | 884.0k | 26.0m | 739.0k | 2.6m | |
Current Assets | 215.5m | 105.6m | 97.9m | 96.6m | 148.8m | 165.8m | 172.2m | 262.7m | 293.3m | 386.4m |
PP&E | 385.0k | 1.3m | 2.9m | 5.8m | 11.1m | 11.5m | 11.5m | 14.8m | 16.7m | 19.9m |
Annual
Quarterly
| USD | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (17.6m) | (10.8m) | (25.2m) | (43.4m) | (22.0m) | (36.5m) | (57.2m) | 104.2m | 114.8m | 95.6m |
Depreciation and Amortization | 43.0k | 48.0k | 104.0k | 264.0k | 554.0k | 1.3m | 2.0m | 834.0k | 1.7m | 2.7m |
Accounts Payable | 317.0k | (182.0k) | 930.0k | 3.6m | 2.5m | 2.7m | 1.1m | 477.0k | (340.0k) | 156.0k |
Cash From Operating Activities | (18.1m) | (7.9m) | (16.3m) | (28.1m) | (17.5m) | (27.0m) | (44.2m) | 58.1m | 128.3m | 108.8m |
| USD | Y, 2018 |
|---|---|
Financial Leverage | 1 x |
Report incorrect company information
Regenxbio Online and Social Media Presence
530 Twitter followers
Regenxbio has 530 Twitter Followers. The number of followers has increased 4.6% month over month and increased 21.9% quarter over quarter
Report incorrect company information
Regenxbio News and Updates
June 05, 2018
Optogenetic Market 2018 Enthralling Growth at A CAGR Of 17% | By Product Type Light Instruments, Actuators, Sensors – Declares MRFR
This report provides in-depth qualitative and overall analysis of the” Optogenetic Market” on a global and regional level from 2018 to 2023. The study also provides a comprehensive review of restraints, Market Dynamics, drivers and opportunities along with their impact on the overall market. The rep…
December 21, 2017
Optogenetic Market Demonstrate Immense Growth Potential at ~176% of CAGR By 2023
This study covers the market dynamics and trends in major countries that are expected to influence the current market scenario and future status of the global Optogenetic Market over the forecast period. Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information
Regenxbio Blogs
October 04, 2018
REGENXBIO Announces Completion of Dosing of Fourth Cohort in Phase I Clinical Trial of RGX-314 Gene Therapy for Wet AMD
Clinical trial evaluates one-time treatment for wet AMD using NAV AAV8 gene therapy A total of 24 patients have been dosed at leading retinal surgery centers in the United States Jeffrey Heier, M.D., to present additional interim Phase I results during the Retina Subspecialty Day at AAO 2018
August 08, 2018
REGENXBIO Announces Proposed Public Offering Of Common Stock
ROCKVILLE, Md. , Aug. 8, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV ® Technology Platform, today announced that it intends to offer and sell,
August 01, 2018
REGENXBIO to Host Conference Call on August 8 to Discuss Second Quarter 2018 Financial Results and Recent Operational Highlights
ROCKVILLE, Md. , Aug. 1, 2018 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV ® Technology Platform, today announced that it will host a conference call
Regenxbio Company Life and Culture
Report incorrect company information
Regenxbio Frequently Asked Questions
When was Regenxbio founded?
Regenxbio was founded in 2009.
Who are Regenxbio key executives?
Regenxbio's key executives are Ken Mills, Vit Vasista and Stephen Yoo.
How many employees does Regenxbio have?
Regenxbio has 107 employees.
What is Regenxbio revenue?
Latest Regenxbio annual revenue is $10.4 m.
What is Regenxbio revenue per employee?
Latest Regenxbio revenue per employee is $97.1 k.
Who are Regenxbio competitors?
Competitors of Regenxbio include Oxford Genetics, Arbutus Biopharma and Encoded Genomics.
Where is Regenxbio headquarters?
Regenxbio headquarters is located at 100 9712 Medical Center Dr, Rockville.
Where are Regenxbio offices?
Regenxbio has an office in Rockville.
How many offices does Regenxbio have?
Regenxbio has 1 office.